Pinnacle Medicines, headquartered in Doylestown, Pennsylvania, is revolutionizing the field of biotechnology with its focus on peptide drug discovery. Founded in 2024, the company aims to transform patients’ lives through its innovative oral peptides. With the slogan "Transforming patients’ lives with oral peptides," Pinnacle is poised to make significant strides in addressing unmet medical needs.
Having secured substantial funding, including an impressive $89.00M Series B round on 01 March 2026, Pinnacle is backed by leading investors such as RA Capital Management, OrbiMed, Foresite Capital, and others. This investment underscores the strong confidence in Pinnacle’s potential to deliver groundbreaking therapeutics by leveraging structure and AI-based drug design tools.
Pinnacle’s leadership is composed of a highly accomplished team with extensive expertise in peptide drug discovery. As the company continues its journey, it presents a compelling opportunity for investors seeking to venture into a promising sector with a significant potential for therapeutic breakthroughs.
